MX2016014299A - Metodo de tratamiento de linfoma no hodgkiniano resistente, meduloblastoma, y/o cancer de pulmon de celulas no pequeñas positivas a alk utilizando compuestos de tienotriazolodiazepina. - Google Patents
Metodo de tratamiento de linfoma no hodgkiniano resistente, meduloblastoma, y/o cancer de pulmon de celulas no pequeñas positivas a alk utilizando compuestos de tienotriazolodiazepina.Info
- Publication number
- MX2016014299A MX2016014299A MX2016014299A MX2016014299A MX2016014299A MX 2016014299 A MX2016014299 A MX 2016014299A MX 2016014299 A MX2016014299 A MX 2016014299A MX 2016014299 A MX2016014299 A MX 2016014299A MX 2016014299 A MX2016014299 A MX 2016014299A
- Authority
- MX
- Mexico
- Prior art keywords
- carbon number
- medulloblastoma
- alk
- halogen atom
- lung cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461987813P | 2014-05-02 | 2014-05-02 | |
| US201461990459P | 2014-05-08 | 2014-05-08 | |
| US201461990469P | 2014-05-08 | 2014-05-08 | |
| PCT/US2015/028798 WO2015168555A1 (en) | 2014-05-02 | 2015-05-01 | Method of treating resistant non-hodgkin lymphoma, medulloblastoma, and/or alk+non-small cell lung cancer using thienotriazolodiazepine compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016014299A true MX2016014299A (es) | 2017-01-27 |
Family
ID=54359380
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016014299A MX2016014299A (es) | 2014-05-02 | 2015-05-01 | Metodo de tratamiento de linfoma no hodgkiniano resistente, meduloblastoma, y/o cancer de pulmon de celulas no pequeñas positivas a alk utilizando compuestos de tienotriazolodiazepina. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20170095484A1 (https=) |
| EP (1) | EP3137086A4 (https=) |
| JP (1) | JP2017514907A (https=) |
| KR (1) | KR20170002550A (https=) |
| CN (1) | CN106687117A (https=) |
| AU (1) | AU2015252940A1 (https=) |
| CA (1) | CA2947593A1 (https=) |
| MX (1) | MX2016014299A (https=) |
| RU (1) | RU2016146102A (https=) |
| WO (1) | WO2015168555A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201506924YA (en) | 2013-03-15 | 2015-09-29 | Incyte Corp | Tricyclic heterocycles as bet protein inhibitors |
| EP3019502B1 (en) | 2013-07-08 | 2017-05-17 | Incyte Holdings Corporation | Tricyclic heterocycles as bet protein inhibitors |
| WO2015081189A1 (en) | 2013-11-26 | 2015-06-04 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
| US9399640B2 (en) | 2013-11-26 | 2016-07-26 | Incyte Corporation | Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors |
| WO2015095492A1 (en) | 2013-12-19 | 2015-06-25 | Incyte Corporation | Tricyclic heterocycles as bet protein inhibitors |
| PL3134403T3 (pl) | 2014-04-23 | 2020-07-13 | Incyte Corporation | 1H-pirolo[2,3-c]pirydyn-7(6H)-ony i pirazolo[3,4-c]pirydyn-7(6H)-ony jako inhibitory białek BET |
| KR20170037670A (ko) * | 2014-08-19 | 2017-04-04 | 온코에틱스 게엠베하 | 티에노트리아졸로디아제핀 화합물을 사용한 림프종의 치료 방법 |
| JP6599979B2 (ja) | 2014-09-15 | 2019-10-30 | インサイト・コーポレイション | Ｂｅｔタンパク質阻害剤として用いるための三環式複素環化合物 |
| US10683305B2 (en) | 2015-04-27 | 2020-06-16 | Concert Pharmaceuticals, Inc. | Deuterated OTX-015 |
| WO2017075377A1 (en) | 2015-10-29 | 2017-05-04 | Incyte Corporation | Amorphous solid form of a bet protein inhibitor |
| CA3028689A1 (en) | 2016-06-20 | 2017-12-28 | Incyte Corporation | Crystalline solid forms of a bet inhibitor |
| CN110996913A (zh) * | 2017-06-30 | 2020-04-10 | 欧恩科斯欧公司 | 新的贝利司他口服制剂 |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
| AU2022243527A1 (en) * | 2021-03-26 | 2023-11-09 | Impact Therapeutics (Shanghai) , Inc | Oral capsule of parp inhibitor and preparation method thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001095912A1 (fr) * | 2000-06-16 | 2001-12-20 | Mitsubishi Pharma Corporation | Compositions permettant de reguler la plage et/ou la vitesse de liberation du ph |
| KR101600634B1 (ko) * | 2007-12-28 | 2016-03-07 | 미쓰비시 타나베 파마 코퍼레이션 | 항암제 |
| PL2902030T3 (pl) * | 2010-05-14 | 2017-07-31 | Dana-Farber Cancer Institute, Inc. | Związki tienotriazolodiazepinowe do leczenia nowotworu |
| AU2013283378B2 (en) * | 2012-06-25 | 2017-07-13 | Oncoethix Gmbh | Method of treating lymphoma using thienotriazolodiazepine compounds |
| JP2015531365A (ja) * | 2012-09-28 | 2015-11-02 | オンコエシックス エスエー | チエノトリアゾロジアゼピン化合物を含む医薬製剤 |
| WO2015018522A1 (en) * | 2013-08-06 | 2015-02-12 | Oncoethix Sa | Bet-bromodomain inhibitor shows synergism with several anti-cancer agents in pre-clinical models of diffuse large b-cell lymphoma (dlbcl) |
| WO2015018520A1 (en) * | 2013-08-06 | 2015-02-12 | Oncoethix Sa | A bet-brd inhibitor represents a novel agent for alk positive anaplastic large cell lymphoma |
| EP3074019A1 (en) * | 2013-11-27 | 2016-10-05 | Oncoethix GmbH | Method of treating non-small-cell lung cancer using pharmaceutical formulation containing thienotriazolodiazepine compounds |
| CN105960239A (zh) * | 2013-11-27 | 2016-09-21 | 翁科埃斯克斯有限公司 | 利用含有噻吩并三唑并二氮杂*化合物的药物制剂治疗白血病的方法 |
-
2015
- 2015-05-01 US US15/308,548 patent/US20170095484A1/en not_active Abandoned
- 2015-05-01 KR KR1020167033941A patent/KR20170002550A/ko not_active Withdrawn
- 2015-05-01 EP EP15786309.3A patent/EP3137086A4/en not_active Withdrawn
- 2015-05-01 WO PCT/US2015/028798 patent/WO2015168555A1/en not_active Ceased
- 2015-05-01 CN CN201580036829.XA patent/CN106687117A/zh active Pending
- 2015-05-01 CA CA2947593A patent/CA2947593A1/en not_active Abandoned
- 2015-05-01 JP JP2017510449A patent/JP2017514907A/ja active Pending
- 2015-05-01 AU AU2015252940A patent/AU2015252940A1/en not_active Abandoned
- 2015-05-01 MX MX2016014299A patent/MX2016014299A/es unknown
- 2015-05-01 RU RU2016146102A patent/RU2016146102A/ru not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2947593A1 (en) | 2015-11-05 |
| WO2015168555A1 (en) | 2015-11-05 |
| JP2017514907A (ja) | 2017-06-08 |
| EP3137086A4 (en) | 2017-12-27 |
| CN106687117A (zh) | 2017-05-17 |
| US20170095484A1 (en) | 2017-04-06 |
| RU2016146102A3 (https=) | 2018-12-17 |
| KR20170002550A (ko) | 2017-01-06 |
| AU2015252940A1 (en) | 2016-11-17 |
| EP3137086A1 (en) | 2017-03-08 |
| RU2016146102A (ru) | 2018-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016014299A (es) | Metodo de tratamiento de linfoma no hodgkiniano resistente, meduloblastoma, y/o cancer de pulmon de celulas no pequeñas positivas a alk utilizando compuestos de tienotriazolodiazepina. | |
| MX2016014301A (es) | Metodo para tratar leucemia mieloide aguda y/o leucemia linfoblastica aguda usando compuestos de tienotriazolodiazepina. | |
| MX2018016267A (es) | Metodo para producir derivado de piridona policiclica sustituida y cristal del mismo. | |
| MX358376B (es) | Nuevos derivados dihidroquinolina-2-ona. | |
| PH12014501719B1 (en) | Pyridone derivatives | |
| MX2014002208A (es) | Inhibidores de serina/treonina quinasa. | |
| NZ718055A (en) | Substituted pyrimidine bmi-1 inhibitors | |
| PH12016502154B1 (en) | Pyridazinone herbicides | |
| MX2012008141A (es) | Compuestos y metodos. | |
| PH12014500584A1 (en) | New bicyclic dihydroquinoline-2-one derivatives | |
| MX2013003960A (es) | Estabilizadores de luz de amina estericamente impedida con funcionalizacion mixta. | |
| MX2015007097A (es) | Nuevas fenil-piridinas/pirazinas bi-anulares para el tratamiento de cancer. | |
| PH12016500148A1 (en) | Plant disease control composition and its use | |
| CY1116662T1 (el) | Μεθοδοι χρησης αναστολεων alk | |
| MX2015001099A (es) | Nuevos derivados biciclicos de piridina. | |
| MY169267A (en) | New aryl-quinoline derivatives | |
| MX2014013074A (es) | Compuestos de n- (tetrazol-5-il) - y n- (triazol-5-il) arilcarboxamida sustituidos y su uso como herbicidas. | |
| JO3509B1 (ar) | معدلات p2x7 | |
| MX343225B (es) | Nuevos derivados de aril-benzocicloalquil-amida. | |
| IN2015DN00446A (https=) | ||
| MX2016014574A (es) | El uso de compuestos de tienotriazolodiazepina para el tratamiento de cancer de mama triple-negativo. | |
| MX2009010461A (es) | Quinolinas y su usoterapeutico. | |
| MX2016005383A (es) | Composiciones para tratar formaciones subterraneas. | |
| MX2016017405A (es) | Compuestos derivados de 2-(3-piridinil)-1h-benzimidazol y medicamentos que los contienen. | |
| MX369470B (es) | Medios y método para el tratamiento de tumores sólidos. |